During the past decade, NC Heart and Vascular Research conducted 53 clinical trials. In the 10-year time frame, 53 clinical trials started and 20 clinical trials were completed, i.e. on average, 37.7% percent of trials that started reached the finish line to date. In the past 5 years, 18 clinical trials started and 9 clinical trials were completed. i.e. 50% of trials that started reached the finish line.

Out of the total clinical trials conducted in "NC Heart and Vascular Research" #1 sponsor was "Abbott Medical Devices" with 8 trials, followed by "Boston Scientific Corporation" with 5 trials sponsored, "C. R. Bard" with 5 trials sponsored, "Medtronic Cardiac Rhythm and Heart Failure" with 3 trials sponsored and "Shockwave Medical, Inc." with 3 trials sponsored. Other sponsors include 40 different institutions and companies that sponsored additional 42 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "NC Heart and Vascular Research" #1 collaborator was "Bard Ltd" with 2 trials as a collaborator, "Eli Lilly and Company" with 2 trials as a collaborator, "Massachusetts General Hospital" with 2 trials as a collaborator, "National Heart, Lung, and Blood Institute (NHLBI)" with 2 trials as a collaborator and "Syntactx" with 2 trials as a collaborator. Other collaborators include 24 different institutions and companies that were collaborators in the rest 34 trials.

According to Clinical.Site data, the most researched conditions in "NC Heart and Vascular Research" are "Peripheral Arterial Disease" (11 trials), "Coronary Artery Disease" (7 trials), "Heart Failure" (7 trials), "Peripheral Artery Disease" (5 trials) and "Atrial Fibrillation" (3 trials). Many other conditions were trialed in "NC Heart and Vascular Research" in a lesser frequency.

Most popular intervention types in "NC Heart and Vascular Research" are "Device" (55 trials), "Drug" (13 trials), "Procedure" (6 trials), "Biological" (2 trials) and "Combination Product" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (5 trials), "Empagliflozin" (2 trials), "Indigo Aspiration System" (2 trials), "XIENCE" (2 trials) and "2nd generation DES (XIENCE family, Promus family, Resolute/Onyx family/Endeavor, and Orsiro stent)" (1 trials). Other intervention names were less common.

The vast majority of trials in "NC Heart and Vascular Research" are 69 trials for "All" genders.

Currently, there are NaN active trials in "NC Heart and Vascular Research". undefined are not yet recruiting, 10 are recruiting, 19 are Active, not recruiting, and 2 are Enrolling by invitation. In total, there were 31 completed trials in NC Heart and Vascular Research, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in NC Heart and Vascular Research, 2 "Phase 1" clinical trials were conducted, 6 "Phase 2" clinical trials and 7 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 46 trials that are defined as “Not Applicable".